RhumbLine Advisers
PTX

RhumbLine Advisers’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

RhumbLine Advisers’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,536
Closed -$48K – 3074
2016
Q1 		$48K Hold
4,536
– – ﹤0.01% 2963
2015
Q4 		$134K Buy
4,536
+806
+22% +$24.4K ﹤0.01% 2904
2015
Q3 		$118K Buy
3,730
+152
+4% +$7.27K ﹤0.01% 2923
2015
Q2 		$212K Buy
3,578
+486
+16% +$34.3K ﹤0.01% 2866
2015
Q1 		$331K Buy
3,092
+470
+18% +$44.8K ﹤0.01% 2554
2014
Q4 		$246K Buy
2,622
+80
+3% +$7.63K ﹤0.01% 2693
2014
Q3 		$195K Hold
2,542
– – ﹤0.01% 2768
2014
Q2 		$228K Buy
2,542
+780
+44% +$47.8K ﹤0.01% 2760
2014
Q1 		$94K Sell
1,762
-85
-5% -$2.81K ﹤0.01% 2929
2013
Q4 		$47K Sell
1,847
-160
-8% -$3.81K ﹤0.01% 3000
2013
Q3 		$55K Sell
2,007
-416
-17% -$13.4K ﹤0.01% 2968
2013
Q2 		$87K Buy
+2,423
New +$90.8K ﹤0.01% 3265

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

RhumbLine Advisers's PTX Position: Q2 2016 in Review

RhumbLine Advisers sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 4,536 shares — an estimated $48K sold.

RhumbLine Advisers first reported a position in PTX in Q2 2013 and held it in 12 quarters. The position peaked at $331K in Q1 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

  • RhumbLine Advisers reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 4,536 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $48K.
  • RhumbLine Advisers first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 12 quarters.
  • RhumbLine Advisers's Pernix Therapeutics Holdings, Inc. position peaked at $331K in Q1 2015.
  • 56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.